J&J’s Rybrevant-based combo could take share from AstraZeneca’s Tagrisso in EGFR-mutant lung cancer, initial data suggest. Just how much will be the subject of debate.
Novo Nordisk acquires late-stage kidney drug for up to $1.3B
The industry awaits a number of readouts and approvals for drugs that address market gaps and enrich treatment landscapes — with huge sales potential to boot.
FDA adcomm backs US WorldMeds’ potential high-risk pediatric neuroblastoma drug
The majority of the FDA adcomm members voted ‘yes’ based on the single-arm, externally controlled study as well as other data and pieces of evidence presented by US WorldMeds.
In all-star immuno-matchup, AbbVie’s Skyrizi bests J&J’s Stelara
Novo’s findings, presented at the European Society of Cardiology Congress and published in the New England Journal of Medicine simultaneously, showed semaglutide resulted in greater weight loss in adults with heart failure with preserved ejection fraction and obesity.
New Alzheimer’s drug raises hopes — along with questions
Pharmaceutical giant Novo Nordisk has turned to influential Black Americans in pursuit of what would be a lucrative victory: having Medicare cover a new class of weight loss drugs.
FDA OK’s Biogen and Sage’s Zurzuvae for postpartum depression, rejects MDD indication
Biogen and Sage’s postpartum depression drug zuranolone was approved by the FDA, but the companies have set their sights on getting it approved for major depressive disorder as well.
